Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility

The first vaccine against SARS-CoV-2 made available in Italy has been BNT162b2, the two-dose mRNA-based vaccine developed by Pfizer-BioNTech. The ASST Fatebenefratelli-Sacco hospital is located in one of the areas most affected by the pandemic, and to date over 2000 healthcare professionals have bee...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Hum Vaccin Immunother
Hoofdauteurs: Gringeri, Michele, Mosini, Giulia, Battini, Vera, Cammarata, Gianluca, Guarnieri, Greta, Carnovale, Carla, Clementi, Emilio, Radice, Sonia
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Taylor & Francis 2021
Onderwerpen:
Letters
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8171003/
https://ncbi.nlm.nih.gov/pubmed/34043934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2021.1917236
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items